Business
CytoMed Therapeutics’ new year update and seeks shareholders’ feedback on proposal to improve shareholder value for their patient capital
SINGAPORE, Jan. 13, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, is pleased to update shareholders as we enter a new exciting year in 2026. As mentioned in previous announcements,
About this update from Cytomed Therapeutics Limited
[{"type":"image","alt":"CYTOMED THERAPEUTICS LIMITED","displaySize":"","headline":null,"caption":"CYTOMED THERAPEUTICS LIMITED","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":139,"url":"https://media.zenfs.com/en/globenewswire.com/a5ea200fbc7d9222864b186d49fef81e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/kZfTE6ya73voiEtLPclhmg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5NTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/a5ea200fbc7d9222864b186d49fef81e","width":300,"height":139}},"lazy":false},{"type":"text","content":"SINGAPORE, Jan. 13, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, is pleased to update shareholders as we enter a new exciting year in 2026. As mentioned in previous announcements, CytoMed through new subsidiary LongevityBank is also diversifying its product pipeline through the process development of clinical-grade cord blood-derived Natural Killer cells. In so doing, it will enhance access to rare and valuable cord blood as sources for cell-based allogeneic therapies. In addition to CytoMed’s gamma delta T cells, Natural Killer cells also express receptors that recognise stress ligands, allowing them to be cytotoxic tools to combat a wide variety of solid and hematological cancers. Notably, CytoMed’s efforts in development of Natural Killer cell therapy has recently received support from Enterprise Singapore, a Singapore government agency championing enterprise development.","length":1207,"tagName":"p"},{"type":"text","content":"For this new year 2026, the Company believes it has enough resources to continue funding its activities for at least a year given our low-cost infrastructure in Southeast Asia. Besides the usual capital market routes, CytoMed can look to licencing and asset monetisation from real estate properties which it owns and uses for operation. We are also continuously exploring proposals with sustainable benefits as we explore with long-term strategic partners including synergistic biotechs and hospitals which can strengthen the business and international aspec...